Please find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/06/2026

ITIDTRtrIIAI PH[R}I[ IIDUtrIRIEX Head off Eic e m a: i3 r 0 : 1 c' o A mu pra ri aB nip cl ee @x, sP ur de am ri su hrn a nH pe ht ra r*il * .P re *m oi ;s e ;s , w 7, " is J.v i. " Road, gorivali (west), Mumbai - 4000ga. BoardLine:+el'22'qzzzltrrl+isilir1t42221116'idilin.).crN: w:Lw5w1.s4ud,SarMshHan2p0ha0r8m*aL, C184se7 sP r L/cs/sE/2026-2027 / 42 Date: L2th August 2026 The Listing Department BSE Scrip Code: 543828 BSE Limited BSE Trading Symbol: SUDARSHAN Phiroze Jeejeebhoy Towers, lSlN: lNE00TVO1,O23 Dalal Street, Mumbai - 400 OO1 Ref: Regulation 33 of sEBl (Listing obligations And Disclosure Requirements) Regutations , zols Sub outcome of the Meeting of Board of Directors of the company held on wednesday, 12th August,2Q26 Dear Sir / lVtadam, Pursuant to Regulation 33 of the SEBI (Listing obligations And Disclosure Requirements) Regulations, 2015' we are submitting herewith Unaudited Standalone & Consolidated Financial Results for the quarter ended on 3oth )une,2026 as approved by the Board of Directors of the Company along-with Auditors' Limited Review Report at its meeting held today. The meeting of the Board of Directors commenced at 5.40 pm and concluded at g.00 pm. we request you to kindly take the above information on record. Thanks & Regards, Yours faithfully, For Sudarshan Pharma lndustries Limited Company Secretary & Regd' off' : 301' Aura Blplex, Above Kalyan Je*ellrs, s.v, Road, Borivati (west), Mumbai - 400092, SUDARSHAN PHARMA INDUSTRIES LTD Head Office: 01, Aura Biplex. Premium Reta Premises E-mail: compliance@sudarshanpharma com Website: .»wsudavshdn::'vamm com Board Line : +91-22-42221111/42221116 (100 line) CIN : L3496ME200SPLC184997 Statement of Unaudited Standalone Financial Results for Quarter Ended June 30, 2026 (Figures are % in Lakhs) (unless specified otherwise '0 'denotes amounts less than X Five Hundred ) Quarter ended Year ended 5 June 30, 2026 | March 31, 2026 | June 30, 2025 | March 31, 2026 = Particulars o (Unaudited) (Unaudited) | (Unaudited) (Audited) Refer note 4 Income: Revenue from operations 16,566.03 19,980.98 14,231.10 66,749.85 Other income 13538 320.79 141.46 84044 A_| Total income 16,701.41 20,301.77 14,372.56 67,500.29 Expenses: Cost of material consumed 107.25 105.65 67.94 297.68 Purchase of stock-in-trade 15,879.80 19,356.54 13,888.58 65,599.01 Changes in inventories of finished goods, stock-in-trade and work- (1,868.15) (2,328.75) (1,212.47) (7,063.44) in-progress Employee benefit expense 172.89 184.80 126.25 618.97 Finance cost 819.46 72739 57130 252974 Depreciation and amortisation expense ; 129.12 100.36 78.98 340.65 Other expenses 647.29 83240 332,60 2,400.87 Total expenses. 15,887.66 18,976.40 13,853.18 64,723.48 [Profit(Loss) before exceptional items and tax for the period (A-B] 813.75 1,323.37 519.38 2,866.82 Exceptional Items - - - - D_|Profit before tax 813.75 1,323.37 519.38 2,866.82 E |Tax expense (@) [Current tax 217.95 315.26 117.00 683.92 (b) [Deferred tax (838, 53.83 29.10 (15.27) F_|Total tax expense (D-E) 209.57 369.09 14610 668.65 G |Net profit for the period/y ear (D-F)_ 604.18 954.28 373.28 2,198.16 H_|Other comprehensive income, net of income tax i) items that will not be reclassified to profit or loss 051 5.53 (1.16)) 2,04 ii) income tax relating to items that will not be reclassified (0.13)) (1.39)] 0.29 0.51)) to profit or loss Total other comprehensive income, net of income tax 038 114 (0.87) 153 1_|Total comprehensive income for the period/ year 604.56 958.42 37241 2,199.69 Paid-up equity share capital : (Face value INR 1 each) 2,496.59 2,406.59 2,406.59 2,406.59 ] [Other equity 12,863.92 K [Earnings per share (in Rs.) From Continuing operations: Basic EPS: (in INR) 025 0.40 015 091 Diluted EPS: (in INR) (Refer note 11) 0.25 0.39 0.15 0.90 For Sudarshan Pharma Industries Limited Sachin Mehta (Joint A DIN : 02211178 Place : Mumbai Date : 12-08-2026 Regd. Off.: 301, Aura Biplex, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai — 400092. SUDARSHAN PHARMA INDUSTRIES LTD Head Office : 301 Aura Biplex Premum Retal Premises, 7. SV Road Bonvali (West! Mumbar - 400092 E-mail : complance @sudarshanpharcmoam. Websif mvmsudarshanpharmacom Board Line : +91-22-42221111/4222{116 ({00 line) CIN : L3496)MH2008PLCI84997 Notes to Standalone Financial Result: 1. The Financial Statement has been reviewed and recommended by Members of the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. The statutory auditors have issued an unmodified report on these results. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and rules amended from time to time. 2. The Company is engaged in manufacturing of API, Jobwork manufacturing in Pharmaceuticals items and traders in chemicals and solvents in India. The Company is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment and the segment wise disclosure requirement of IND AS 108 on operating segment is not applicable to it. 3. The previous periods’ figures have been re-grouped / re-arranged / re-casted wherever necessary to make it comparable with the current period. 4. The figures for the quarter ended March 31, 2026 is the balancing figures between the unaudited figures in respect of the quarters were subjected to limited review by the Statutory Auditors. The management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company’s affairs. The Auditor’s Limited Review Report of the statutory auditors is being filed with BSE Limited and is also available on the Company's website www sudarshanpharma.com. 5. The Statutory Auditors have conducted a limited review of the above mentioned quarterly results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Report of the statutory auditors will be uploaded on the BSE portal along with the results and is also available on the Company's website www sudarshanpharma.com. 6. During the quarter ended 30th June 2026, the Company decided to discontinue its manufacturing operations at the Palghar unit. The decision was taken after evaluating the unit's operating performance and its contribution to the Company’s financial results. The closure is expected to help the Company rationalize fixed and operating costs, minimize further losses, and enable management to focus its resources on more sustainable and profitable operations. 7. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (i) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Nine Crores Eighteen Lakhs Eighty-Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made. Till 30th June, 2026, the Company had received an amount of Rs.4,68,00,535/- (including interest) out of the total outstanding amount and the balance would be received by the Company in future. Regd. Off.: 301, Aura Biplex, Above Kalyan Jewellers, S V Road, B v Il) (West) Mumbai— 400092. SUDARSHAN PHARMA INDUSTRIES LTD Head Office: 301 Aura Biplex. Premium Retall, Premises, 7, SV. Road, Borvali (West). Mumbai - 400092 E-mail : compliance@sudarshanpharma.com. Website : www sudarshanpharma com Board Line : $91-22-42221111/42221116 (100 line) CIN : L31496MHE2008PLC184997 The Board of Directors of [Showing first 8,000 characters — download PDF for full document]